What Researchers Did
Researchers developed and tested a pressure-resistant housing, the 'Hyperbaric Protective Tube,' to safely conduct hyperbaric oxygen therapy (HBOT) for a patient with a left ventricular assist device (LVAD).
What They Found
A 65-year-old male with a life-threatening soft tissue infection and an LVAD underwent 30 uneventful HBOT sessions using the protective tube. This intervention led to clinical improvement of the infection and extended the timeframe for awaiting heart transplantation.
What This Means for Canadian Patients
This innovation could potentially allow Canadian patients with LVADs who require hyperbaric oxygen therapy for severe infections to receive this treatment safely. It offers a practical solution for managing medical devices not formally approved for hyperbaric conditions, expanding treatment options for a vulnerable patient population.
Canadian Relevance
This study has no direct Canadian connection as it was conducted in Europe.
Study Limitations
A significant limitation of this study is that it describes a single case, limiting the generalizability of the findings.